Article Text
PDF
Statistics from Altmetric.com
Pfizer would like to acknowledge the case study titled ‘Sayana Press and a case of likely lipoatrophy’1 published online in BMJ Sexual & Reproductive Health in June 2018.
Sayana Press (medroxyprogesterone acetate) is indicated for long-term female contraception and may be administered by a healthcare professional (HCP) or, when considered appropriate by the HCP, self-injected by the patient, with medical follow up as necessary in accordance with local clinical guidance. Each subcutaneous injection prevents ovulation and provides contraception for at least 13 weeks (+/– 1 week).2
The Sayana Press Summary of Product Characteristics states under ‘Section 4.8 Undesirable effects’ that injection-site reactions such as persistent injection-site atrophy/indentation/dimpling, injection-site nodule/lump and injection-site pain/tenderness are commonly reported (occurring in ≥ 1/100 to <1/10) and lipodystrophy …
Footnotes
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests SP is the Medical Director at Pfizer Essential Health UK, the manufacturer of Sayana Press.
Patient consent Not required.
Provenance and peer review Commissioned; internally peer reviewed.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.